Top Markets
Coin of the day
NovaBridge Biosciences NovaBridge Biosciences

NovaBridge Biosciences

NBP
주식 순위 #18279
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering... NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
주가
$1.79
마지막 동기화: 2026-09-02
시가총액
$205.75M
변동 (1일)
3.18%
변동 (1년)
-61.61%
국가
US
거래 NovaBridge Biosciences (NBP)

카테고리

NovaBridge Biosciences (NBP)의 주가 이력
최고 종가: $1.76 (2026-09-01 기준)

최저 종가: $13.69 (2020-01-01 기준)
NovaBridge Biosciences의 주가 이력 (2020 ~ 2026)
연간 주가 성과
연도 성과
2026 (TTM) -24.42%
2025 320.81%
2024 -37.56%
2023 -57.87%
2022 -92.59%
2021 24.83%
2020 0.00%
유사 기업 또는 경쟁사의 주가
회사 주가 변동률 1년% 국가
$556.43 40.29%
US
$1.05K 45.39%
NL
$152.82 535.43%
US
$123.05 -8.95%
AU
$757.71 6.76%
CH